1. IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?

3. Introduction/Overview

4. Biology of Immunoglobulin G

5. Fc Fused-FVIII: Immunomodulation and Tolerogenics

6. rFVIIIFc: Reduced Immunogenicity and Induction of Tolerance in Hemophilia A Mice

7. Fc Fusion Proteins and Neonatal Exposure

8. Fc Fusion of FVIII and Half-Life Prolongation

9. PEGylation of FVIII and Half-Life Prolongation

10. PEGylated FVIII: Immunomodulation and Tolerogenics

11. rVIII-SingleChain (CSL627) and Half-Life Prolongation

12. The Impact of Modified Pharmacokinetics of EHL Agents on Clinical Practice

13. Safety/Efficacy Data Supporting the Benefits of EHL Agents in Hem-A

14. FVIII Fc Fusion Protein (rFVIIIFc): A-LONG Study Design

15. FVIII Activity vs Time Profile for EHL rFVIIIFc and Standard rFVIII: A-LONG

16. FVIII Fc Fusion Protein (rFVIIIFc): Kids A-LONG Trial Methods and Results

17. Safety and Efficacy of BAY 94-9027: Study Design of PROTECT VIII

18. PROTECT VIII Summary Results: Bleeding and Dosing

19. Interim Analysis of Pathfinder™3 Trial

20. rVIII-SingleChain (CSL627): AFFINITY Study Design

21. AFFINITY Results: Treatment Regimens Prior to Study Entry and at Study End

22. Case Study 1: Previously Untreated Patient

23. Case Study 2: Switching a Previously Treated Patient From Standard rFVIII to EHL rFVIIIFc

24. Case Study 2: FVIII Activity in Prophylactically Treated Patient Switched to rFVIIIFc Fusion Protein

25. Factors to Consider When Personalizing Prophylaxis

26. Case Study 3: Patient With Inhibitors, Rescue ITI With rFVIIIFc

27. Case Study 3: Patient With Inhibitors, Rescue ITI With rFVIIIFc (cont’d)

28. Application of EHL rFVIII Replacement Agents for ITI

29. Summary and Conclusions

30. Abbreviations

31. Abbreviations (cont)